Physician profile
Gordon E Harmston
NPI 1972516748
$1,253.87
in general payments reported to CMS, 2019-2025
18 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $62.91 · 2021: $12.44 · 2022: $53.38 · 2023: $28.28 · 2024: $225 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.32 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.85 | 2019-2025 | |
| Gilead Sciences, INC. | $177.88 | 2019-2025 | |
| Madrigal Pharmaceuticals | $137.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $121.72 | 2022-2025 | Tremfya |
| Pfizer INC. | $103.30 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.40 | 2019-2025 | Entyvio |
| Orphalan INC | $87.41 | 2025 | Cuvrior |
| Organon LLC | $61.27 | 2024-2025 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $49.80 | 2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $34.80 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.64 | 2020-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $32.06 | 2020-2025 | |
| Shionogi INC | $25.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.84 | 2025 | |
| Ucb, INC. | $14.63 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.42 | 2019 | |
| Merck Sharp & Dohme LLC | $12.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Harmston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.